Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device: A prospective controlled multicenter study

Charles M. Luetje, Derald Brackman, Thomas J. Balkany, Jennifer Maw, R. Stanley Baker, David Kelsall, Douglas Backous, Richard Miyamoto, Simon Parisier, Alexander Arts

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

OBJECTIVES: The goal of the study was to evaluate the performance of a semi-implantable middle ear hearing device (Vibrant Soundbridge System (VSB); Symphonix Devices, Inc). STUDY DESIGN: A prospective, single-subject, repeated-measures multicenter study was conducted to determine the safety and efficacy of the VSB using analog and digital external processors. Measures included residual hearing, functional gain, speech recognition, acoustic feedback, occlusion, and patient self-assessment to determine satisfaction, perceived performance, and device preference compared with an appropriately fit acoustic hearing aid. Fifty-three adult subjects with moderate to severe sensorineural hearing loss were evaluated at 4 or more intervals after implantation. RESULTS: Improvements in satisfaction, performance, and preference were statistically significant with the VSB, as was functional gain across all test frequencies (P < 0.001). Occlusion and feedback were virtually eliminated. Aided speech recognition was comparable between VSB and the hearing aid. Residual hearing was unchanged. CONCLUSION: The VSB is a safe and effective treatment option for adults with moderate to severe sensorineural hearing loss.

Original languageEnglish
Pages (from-to)97-107
Number of pages11
JournalOtolaryngology - Head and Neck Surgery
Volume126
Issue number2
DOIs
StatePublished - Feb 2002

Fingerprint

Phase III Clinical Trials
Middle Ear
Hearing
Multicenter Studies
Hearing Aids
Sensorineural Hearing Loss
Equipment and Supplies
Speech Acoustics
Acoustics
Safety
Therapeutics

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device : A prospective controlled multicenter study. / Luetje, Charles M.; Brackman, Derald; Balkany, Thomas J.; Maw, Jennifer; Baker, R. Stanley; Kelsall, David; Backous, Douglas; Miyamoto, Richard; Parisier, Simon; Arts, Alexander.

In: Otolaryngology - Head and Neck Surgery, Vol. 126, No. 2, 02.2002, p. 97-107.

Research output: Contribution to journalArticle

Luetje, Charles M. ; Brackman, Derald ; Balkany, Thomas J. ; Maw, Jennifer ; Baker, R. Stanley ; Kelsall, David ; Backous, Douglas ; Miyamoto, Richard ; Parisier, Simon ; Arts, Alexander. / Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device : A prospective controlled multicenter study. In: Otolaryngology - Head and Neck Surgery. 2002 ; Vol. 126, No. 2. pp. 97-107.
@article{11dbc05788f84186a973fe20e2f36a56,
title = "Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device: A prospective controlled multicenter study",
abstract = "OBJECTIVES: The goal of the study was to evaluate the performance of a semi-implantable middle ear hearing device (Vibrant Soundbridge System (VSB); Symphonix Devices, Inc). STUDY DESIGN: A prospective, single-subject, repeated-measures multicenter study was conducted to determine the safety and efficacy of the VSB using analog and digital external processors. Measures included residual hearing, functional gain, speech recognition, acoustic feedback, occlusion, and patient self-assessment to determine satisfaction, perceived performance, and device preference compared with an appropriately fit acoustic hearing aid. Fifty-three adult subjects with moderate to severe sensorineural hearing loss were evaluated at 4 or more intervals after implantation. RESULTS: Improvements in satisfaction, performance, and preference were statistically significant with the VSB, as was functional gain across all test frequencies (P < 0.001). Occlusion and feedback were virtually eliminated. Aided speech recognition was comparable between VSB and the hearing aid. Residual hearing was unchanged. CONCLUSION: The VSB is a safe and effective treatment option for adults with moderate to severe sensorineural hearing loss.",
author = "Luetje, {Charles M.} and Derald Brackman and Balkany, {Thomas J.} and Jennifer Maw and Baker, {R. Stanley} and David Kelsall and Douglas Backous and Richard Miyamoto and Simon Parisier and Alexander Arts",
year = "2002",
month = "2",
doi = "10.1067/mhn.2002.122182",
language = "English",
volume = "126",
pages = "97--107",
journal = "Otolaryngology - Head and Neck Surgery",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device

T2 - A prospective controlled multicenter study

AU - Luetje, Charles M.

AU - Brackman, Derald

AU - Balkany, Thomas J.

AU - Maw, Jennifer

AU - Baker, R. Stanley

AU - Kelsall, David

AU - Backous, Douglas

AU - Miyamoto, Richard

AU - Parisier, Simon

AU - Arts, Alexander

PY - 2002/2

Y1 - 2002/2

N2 - OBJECTIVES: The goal of the study was to evaluate the performance of a semi-implantable middle ear hearing device (Vibrant Soundbridge System (VSB); Symphonix Devices, Inc). STUDY DESIGN: A prospective, single-subject, repeated-measures multicenter study was conducted to determine the safety and efficacy of the VSB using analog and digital external processors. Measures included residual hearing, functional gain, speech recognition, acoustic feedback, occlusion, and patient self-assessment to determine satisfaction, perceived performance, and device preference compared with an appropriately fit acoustic hearing aid. Fifty-three adult subjects with moderate to severe sensorineural hearing loss were evaluated at 4 or more intervals after implantation. RESULTS: Improvements in satisfaction, performance, and preference were statistically significant with the VSB, as was functional gain across all test frequencies (P < 0.001). Occlusion and feedback were virtually eliminated. Aided speech recognition was comparable between VSB and the hearing aid. Residual hearing was unchanged. CONCLUSION: The VSB is a safe and effective treatment option for adults with moderate to severe sensorineural hearing loss.

AB - OBJECTIVES: The goal of the study was to evaluate the performance of a semi-implantable middle ear hearing device (Vibrant Soundbridge System (VSB); Symphonix Devices, Inc). STUDY DESIGN: A prospective, single-subject, repeated-measures multicenter study was conducted to determine the safety and efficacy of the VSB using analog and digital external processors. Measures included residual hearing, functional gain, speech recognition, acoustic feedback, occlusion, and patient self-assessment to determine satisfaction, perceived performance, and device preference compared with an appropriately fit acoustic hearing aid. Fifty-three adult subjects with moderate to severe sensorineural hearing loss were evaluated at 4 or more intervals after implantation. RESULTS: Improvements in satisfaction, performance, and preference were statistically significant with the VSB, as was functional gain across all test frequencies (P < 0.001). Occlusion and feedback were virtually eliminated. Aided speech recognition was comparable between VSB and the hearing aid. Residual hearing was unchanged. CONCLUSION: The VSB is a safe and effective treatment option for adults with moderate to severe sensorineural hearing loss.

UR - http://www.scopus.com/inward/record.url?scp=19044374316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19044374316&partnerID=8YFLogxK

U2 - 10.1067/mhn.2002.122182

DO - 10.1067/mhn.2002.122182

M3 - Article

C2 - 11870337

AN - SCOPUS:19044374316

VL - 126

SP - 97

EP - 107

JO - Otolaryngology - Head and Neck Surgery

JF - Otolaryngology - Head and Neck Surgery

SN - 0194-5998

IS - 2

ER -